Terms ending in 2036
Every in-force patent on Glytec, LLC's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,886,556 | Diabetes Management Therapy Advisor In force · High confidence | Glytec, LLC | In force | High confidence | |
| US 10,380,328 | Diabetes Management Therapy Advisor In force · High confidence | Glytec, LLC | In force | High confidence | |
| US 11,574,742 | Diabetes Management Therapy Advisor In force · Low confidence | Glytec, LLC | In force | Low confidence | |
| US 12,040,096 | Diabetes Management Therapy Advisor In force · High confidence | Glytec, LLC | In force | High confidence | |
| US 12,725,715 | Diabetes Management Therapy Advisor In force · Medium confidence | Glytec, LLC | In force | Medium confidence | |
| US 11,200,988 | Diabetes Management Therapy Advisor In force · Medium confidence | Glytec, LLC | In force | Medium confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.